This profile is for informational purposes only and is not medical advice. Consult a healthcare professional before use. See full terms.
Donepezil
A reversible acetylcholinesterase inhibitor (marketed as Aricept) that is FDA-approved for Alzheimer's disease and is one of the most widely prescribed cognitive enhancers globally.
Benefits
What is Donepezil?
Donepezil (marketed as Aricept by Eisai and Pfizer) is a centrally-acting, reversible acetylcholinesterase inhibitor that is one of the most extensively studied and widely prescribed medications for cognitive impairment. Approved by the FDA in 1996 for the treatment of mild-to-moderate Alzheimer's disease, and later expanded to include severe Alzheimer's, Donepezil works by inhibiting the enzyme acetylcholinesterase (AChE), thereby preventing the breakdown of acetylcholine in the synaptic cleft and increasing cholinergic neurotransmission. Multiple large-scale randomised controlled trials, including the landmark studies by Rogers et al. (1998) in Neurology, have demonstrated statistically significant improvements in cognitive function as measured by the ADAS-cog scale, as well as improvements in global clinical impression scores in Alzheimer's patients.
Beyond its established role in Alzheimer's treatment, Donepezil has attracted interest for potential off-label cognitive enhancement in healthy individuals and those with other cognitive disorders. Studies have explored its use in vascular dementia, traumatic brain injury, post-anaesthesia cognitive dysfunction, and even as a cognitive enhancer in healthy pilots undergoing altitude-related cognitive impairment. A study by Yesavage et al. (2002) in Neurology demonstrated that Donepezil improved retention of complex aviation tasks in healthy older pilots. Additionally, research has identified neuroprotective effects independent of cholinesterase inhibition, including modulation of glutamate-mediated excitotoxicity, upregulation of nicotinic acetylcholine receptors, and anti-inflammatory properties. The drug has a long half-life of approximately 70 hours, allowing once-daily dosing, and has been prescribed to millions of patients worldwide since its approval.
- Acetylcholinesterase inhibition: Selectively and reversibly inhibits acetylcholinesterase (AChE) in the central nervous system, preventing the hydrolysis of acetylcholine and increasing its concentration and duration of action at cholinergic synapses
- Selectivity for central AChE: Demonstrates approximately 1,000-fold selectivity for AChE over butyrylcholinesterase (BuChE), resulting in fewer peripheral cholinergic side effects compared to non-selective inhibitors
- Nicotinic receptor upregulation: Chronic treatment leads to upregulation of nicotinic acetylcholine receptors (particularly alpha-7 nAChR), which are involved in attention, working memory, and synaptic plasticity
- Neuroprotective effects: Independent of cholinesterase inhibition, Donepezil has been shown to protect neurons against glutamate-mediated excitotoxicity, oxidative stress, and beta-amyloid-induced toxicity in cell culture and animal models
- Anti-inflammatory properties: Modulates microglial activation and reduces neuroinflammatory markers, contributing to neuroprotection through suppression of chronic neuroinflammation
- Cerebral blood flow enhancement: Increases regional cerebral blood flow through cholinergic vasodilation of cerebral arterioles, improving nutrient and oxygen delivery to metabolically active brain regions
- Alzheimer's starting dose: 5 mg once daily at bedtime, taken for 4-6 weeks before considering dose escalation to allow tolerability assessment
- Alzheimer's maintenance dose: 10 mg once daily at bedtime; a 23 mg extended-release formulation is available for patients with moderate-to-severe Alzheimer's disease
- Off-label cognitive enhancement: Lower doses of 2.5-5 mg have been explored in research settings for cognitive enhancement in non-demented individuals, though this is not an approved indication
- Timing and administration: Typically taken at bedtime due to cholinergic side effects (nausea, vivid dreams); can be taken with or without food; tablet and orally disintegrating formulations available
- Long half-life: The elimination half-life of approximately 70 hours means steady-state is reached in about 2-3 weeks, and effects persist for days after discontinuation
- Common side effects: Gastrointestinal effects are most frequent, including nausea (11%), diarrhoea (10%), and vomiting, typically occurring during dose initiation or escalation and often resolving with continued use
- Vivid dreams and insomnia: Cholinergic enhancement can cause vivid dreams, nightmares, and sleep disturbances, which is why bedtime administration is recommended
- Cardiovascular effects: Can cause bradycardia, particularly in patients with underlying cardiac conduction abnormalities; ECG monitoring may be warranted in at-risk patients
- Cholinergic crisis risk: Overdose can produce cholinergic crisis characterised by severe nausea, vomiting, salivation, sweating, bradycardia, hypotension, and respiratory depression
- Drug interactions: Metabolised primarily by CYP2D6 and CYP3A4; interacts with strong inhibitors (ketoconazole, paroxetine) and inducers (rifampicin, carbamazepine) of these enzymes
- Muscle effects: May cause muscle cramps, fatigue, and in rare cases rhabdomyolysis, particularly when combined with other drugs that affect muscle metabolism
Natural Sources & Forms
- Rogers et al. (1998): "Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study" in Neurology, one of the pivotal trials leading to FDA approval
- Yesavage et al. (2002): "Donepezil and flight simulator performance: effects on retention of complex skills" in Neurology, demonstrating cognitive enhancement in healthy older adults
- Birks and Harvey (2018): Cochrane systematic review "Donepezil for dementia due to Alzheimer's disease" providing comprehensive meta-analysis of efficacy and safety data
- FDA prescribing information: Complete prescribing information for Aricept (donepezil hydrochloride) including pharmacokinetics, clinical trial data, and safety warnings
- Sharma (2019): "Cholinesterase inhibitors as Alzheimer's therapeutics" in Molecular Medicine Reports, reviewing the mechanisms and clinical evidence for donepezil and related agents
Frequently Asked Questions
A reversible acetylcholinesterase inhibitor (marketed as Aricept) that is FDA-approved for Alzheimer's disease and is one of the most widely prescribed cognitive enhancers globally.
The key benefits of Donepezil include: Cognitive Enhancement, Focus, Longevity, Memory, Mood.
Acetylcholinesterase inhibition: Selectively and reversibly inhibits acetylcholinesterase (AChE) in the central nervous system, preventing the hydrolysis of acetylcholine and increasing its concentration and duration of action at cholinergic synapses Selectivity for central AChE: Demonstrates approximately 1,000-fold selectivity for AChE over butyrylcholinesterase (BuChE), resulting in fewer peripheral cholinergic side effects compared to non-selective inhibitors Nicotinic receptor upregulation: Chronic treatment leads to upregulation of nicotinic acetylcholine receptors (particularly alpha-7 nAChR), which are involved in attention, working memory, and synaptic plasticity Neuroprotective effects: Independent of cholinesterase inhibition, Donepezil has been shown to protect neurons against glutamate-mediated excitotoxicity, oxidative stress, and beta-amyloid-induced toxicity in cell culture and animal models Anti-inflammatory properties: Modulates microglial activation and reduces neuroinflammatory markers, contributing to neuroprotection through suppression of chronic neuroinflammation Cerebral blood flow enhancement: Increases regional cerebral blood flow through cholinergic vasodilation of cerebral arterioles, improving nutrient and oxygen delivery to metabolically active brain regions
Alzheimer's starting dose: 5 mg once daily at bedtime, taken for 4-6 weeks before considering dose escalation to allow tolerability assessment Alzheimer's maintenance dose: 10 mg once daily at bedtime; a 23 mg extended-release formulation is available for patients with moderate-to-severe Alzheimer's disease Off-label cognitive enhancement: Lower doses of 2.5-5 mg have been explored in research settings for cognitive enhancement in non-demented individuals, though this is not an approved indication Timing and administration: Typically taken at bedtime due to cholinergic side effects (nausea, vivid dreams); can be taken with or without food; tablet and orally disintegrating formulations available Long half-life: The elimination half-life of approximately 70 hours means steady-state is reached in about 2-3 weeks, and effects persist for days after discontinuation
Common side effects: Gastrointestinal effects are most frequent, including nausea (11%), diarrhoea (10%), and vomiting, typically occurring during dose initiation or escalation and often resolving with continued use Vivid dreams and insomnia: Cholinergic enhancement can cause vivid dreams, nightmares, and sleep disturbances, which is why bedtime administration is recommended Cardiovascular effects: Can cause bradycardia, particularly in patients with underlying cardiac conduction abnormalities; ECG monitoring may be warranted in at-risk patients Cholinergic crisis risk: Overdose can produce cholinergic crisis characterised by severe nausea, vomiting, salivation, sweating, bradycardia, hypotension, and respiratory depression Drug interactions: Metabolised primarily by CYP2D6 and CYP3A4; interacts with strong inhibitors (ketoconazole, paroxetine) and inducers (rifampicin, carbamazepine) of these enzymes Muscle effects: May cause muscle cramps, fatigue, and in rare cases rhabdomyolysis, particularly when combined with other drugs that affect muscle metabolism
Overall Rating
Log in to rate this nootropic.
Comments
Log in to leave a comment.
No comments yet. Be the first to share your experience!